urogen.com (URGN): Operating Profitability

Brandmark of UroGen Pharma Corp (URGN)

UroGen Pharma Ltd. (URGN) dominates the non-invasive bladder cancer therapy niche through its unique hydrogels. Operating margins demonstrate the business's efficiency dynamics, where -12.40 reflects the latest metric value. The company is implementing algorithmic molecule design with synthesis automation, while drug production is delegated to external contract manufacturing organizations to optimize production capacities.

URGN - UroGen Pharma Operating Profit Rate over the range 07/04/2022 - 11/20/2026

UroGen Pharma Ltd. - analytical breakdowns and key metrics (URGN)

- share price and consensus valuation forecast:
- stock exchange capitalization data:
Basic company analysis:URGN, UroGen
Finished products of UroGen Pharma Corp

Investors use this metric to evaluate cost management efficiency and the quality of the business's operating cycle. The metric is calculated as the ratio of operating profit to revenue, excluding the impact of debt load and the tax regime. For UroGen Pharma Ltd. (URGN), this reflects the returns from licensing gel technologies and partnerships with urological clinics. Analyzing the operating margin (EBIT margin) helps identify growth points or the risk of a drawdown. The trend in this operating margin confirms the stability of the fundamental model.

Competitor analysis for UroGen Pharma Ltd.

Operating Profitability BeiGene Ltd|Halozyme Therapeutics - Operating Profit Margin|Operating Sales Margin RVMD (Revolution Medicines Corp)|Operating Profit Ratio AAPG|Operating Profitability CG Oncology Therapeutics CGON|Operating Profit Rate BCAX|PSNL - Operating Profitability|Profitability of Operations Erasca Oncology ERAS|delcath.com (DCTH) - Operating Profitability|Y-mAbs Therapeutics - Operating Profit Rate|AURA (Aura Biosciences Inc) - Operating Margin|Operating Return on Sales candeltx.com CADL|Operating Margin ARAY|SLS (SELLAS Life Sciences Group, Inc.) - Operating Profit Rate|Operating Profitability Actuate Therapeutics, Inc. ACTU|citiusonc.com - Operating Profitability|TuHURA Biosciences Inc. - Operating Margin|TARA - Operating Margin|FATE (Fate Therapeutics) - Operating Sales Margin|Operating Sales Margin Aadi Bioscience, Inc.|Operating Sales Margin TCRX|Operating Profitability CSBR|Operating Margin XBIT|Profitability of Operations CEL-SCI Corp.|Operating Profitability ostherapies.com OSTX|RADX: Return on Sales by Operating Profit|ARTV: Operating Sales Margin|ANL (Adlai Nortye) - Return on Sales by Operating Profit|Veru (VERU) - Operating Profitability|Operating Sales Margin Tempest Therapeutics Inc|Operating Profitability Xilio Therapeutics|Return on Sales by Operating Profit RENB (Renovaro Inc.)|Operating Profitability Mural Oncology PLC (MURA)|Operating Margin Kairos Pharma (KAPA)|Operating Profitability onkuretherapeutics.com OKUR|GDTC: Return on Sales by Operating Profit|CRIS: Operating Sales Margin|apollomicsinc.com (APLM) - Operating Sales Margin|THAR: Operating Margin|Operating Sales Margin Advanced Biomed Inc.|Operating Sales Margin GNPX|Return on Sales by Operating Profit CLDI (Calidi Biotherapeutics)|Operating Margin SBFM|Xenetic Biosciences, Inc. - Return on Sales by Operating Profit|Operating Profitability Salarius Pharmaceuticals SLRX|Operating Margin purple-biotech.com PPBT|AONC - Operating Profitability|BGNE: Operating Profitability|CKPT: Operating Margin|Elevation Oncology - Operating Profit Rate|ICAD (iCAD) - Operating Margin|IKNA: Operating Profit Rate|Operating Profitability Notable Labs (NTBL)|VIRX (Viracta Therapeutics, Inc.) - Operating Profit Rate|Operating Profitability MorphoSys Corporation MOR|NAYA: Return on Sales by Operating Profit|Ascentage Pharma Group International - Operating Margin